D
Adamis Pharmaceuticals Corporation ADMP
$0.2113 -$0.0087-3.96%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
D
Sell 11/10/2022Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from D- on 11/10/2022 due to an increase in the volatility index.
D
Sell 10/26/2022Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to D- from D on 10/26/2022 due to a decline in the total return index and volatility index.
D
Sell 8/30/2022Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from D- on 8/30/2022 due to an increase in the volatility index and total return index.
D
Sell 8/15/2022Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the growth index, total return index and valuation index. Total revenue declined 96.55% from $1.15M to $39.8, operating cash flow declined 41.64% from -$6.99M to -$9.89M, and EBIT declined 3.32% from -$7.91M to -$8.18M.
D
Sell 5/18/2022Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from D- on 5/18/2022 due to a noticeable increase in the growth index. Total revenue increased 199.58% from -$1.16M to $1.15M, and EBIT increased 16.23% from -$9.45M to -$7.91M.
D
Sell 5/13/2022Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to D- from D on 5/13/2022 due to a decline in the total return index and volatility index.
D
Sell 4/21/2022Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from E+ on 4/21/2022 due to an increase in the volatility index.
E
Sell 4/20/2022Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index and volatility index.
D
Sell 11/9/2021Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from E+ on 11/9/2021 due to an increase in the total return index and volatility index.
E
Sell 11/8/2021Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to E+ from D on 11/8/2021 due to a significant decline in the growth index, solvency index and valuation index. Debt to equity increased from 0.21 to 1.64, earnings per share declined from -$0.1032 to -$0.2199, and EBIT declined 101.45% from -$6.84M to -$13.78M.
D
Sell 5/1/2020Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from D- on 5/1/2020 due to a substantial increase in the growth index and valuation index. Operating cash flow increased 30.99% from -$4.26M to -$2.94M, earnings per share increased from -$0.1244 to -$0.0919, and EBIT increased 19.27% from -$7.01M to -$5.66M.
D
Sell 1/9/2018Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to D- from D on 1/9/2018 due to a decline in the volatility index and valuation index.
D
Sell 12/15/2017Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from D- on 12/15/2017 due to an increase in the volatility index and total return index.
D
Sell 11/30/2017Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to D- from D on 11/30/2017 due to a decline in the volatility index and total return index.
D
Sell 11/15/2017Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from D- on 11/15/2017 due to a major increase in the total return index, valuation index and growth index. Operating cash flow increased 16.42% from -$3.47M to -$2.9M.
D
Sell 3/11/2016Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index, total return index and valuation index.
D
Sell 4/28/2014Upgraded
Adamis Pharmaceuticals Corporation (ADMP) was upgraded to D from D- on 4/28/2014 due to a noticeable increase in the volatility index and valuation index.
D
Sell 3/17/2014Downgrade
Adamis Pharmaceuticals Corporation (ADMP) was downgraded to D- from D on 3/17/2014 due to a major decline in the volatility index.
Weiss Ratings